Russian vaccines against COVID-19 are effective, claims Vladimir Putin

Russian vaccines against COVID-19 are effective, claims Vladimir Putin

Advertisement
Russian vaccines against COVID-19 are effective, claims Vladimir PutinASSAM

MOSCOW: Russian President Vladimir Putin on Tuesday said that all Russian vaccines against COVID-19 are "effective." He further added that the country would soon register a third shot against the virus.

The President also said that Moscow was ready to cooperate with all other countries on the virus, but urged against "politicizing" the process.

Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease.

Also Read: Pfizer says its Covid-19 vaccine is “90 percent effective” in Phase 3 trial

In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well.

The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms.
Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November.

To support our brand of fearless and investigative journalism, support us HERE.

Download:                                                                  

The Inside Northeast app HERE for News, Views, and Reviews from Northeast India.

Do keep following us for news on-the-go. We deliver the Northeast.

Edited By: Admin
Published On: Nov 10, 2020
POST A COMMENT